Johnson & Johnson Acquires Firefly Bio for $1 Billion to Deliver Protein Degraders into Cancer Cells
The Firelink platform uses antibodies to carry targeted protein degraders in an effort to address difficult-to-drug targets in solid tumors; the transaction has been completed, but efficacy, safety, and candidate drug progress remain undisclosed.